🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We’re looking forward to taking part in a fireside chat at SVB Securities’ 2023 Global Biopharma Conference tomorrow – check out more information on our presentation here: bit.ly/3E3lV38

Our leadership team had a great time at SVB Securities’ 2023 Global Biopharma Conference engaging with other industry professionals on this year’s hot topics across the sector.

As #NationalCancerResearchMonth comes to a close, we'd like to thank the researchers at iTeos for their continued dedication to develop life-saving treatments for those with cancer. Learn more about iTeos's innovative treatments here: iteostherapeutics.com/pipeline/

Immunotherapy is a treatment that boosts your own immune system to fight cancer. Each week during Cancer #Immunotherapy Awareness Month, we'll be sharing facts and the history to raise awareness and highlight the future of cancer treatments.

#DYK the first successful treatment of a cancer patient with immunotherapy was in 1891 by The Father of Immunotherapy, Bradley Coley. We've come a long way in immunotherapy treatment since then! Cancer #Immunotherapy Awareness Month

iTeos is developing a next-generation immuno-oncology, anti-TIGIT candidate belrestotug, which is currently being evaluated in ongoing Phase 2 and Phase 1b programs. Hear more from our President & CEO Michel Detheux:

Your immune system works through a two-pronged approach with innate and adaptive responses. iTeos' anti-TIGIT candidate, belrestotug, is designed to activate multiple immune cells like T Cells and NK Cells to destroy tumor cells. Learn more here: bit.ly/43GTum9

We leverage our deep understanding of the adenosine pathway to identify and develop potential treatments, like EOS-984, our latest first-in-class small molecule for advanced malignancies. Learn more about our unique approach to #Immunotherapy here: iteostherapeutics.com/pipeline/

Immunotherapy has revolutionized cancer treatment and continues to provide critical advances in care. Learn more about how iTeos is working to improve the clinical benefit of oncology therapies #Immunotherapy iteostherapeutics.com

The most common type of lung cancer is NSCLC - it accounts for 85% of the 238,000 cases in the US, there continues to be a strong need for more effective treatments. Learn more about iTeos's clinical trials in #NSCLC with a targeted #immunotherpy approach: iteostherapeutics.com/pipeline/clini…

Today we announced our second quarter 2023 financial results and provided business updates. Read the press release here: investors.iteostherapeutics.com/news-releases/… $ITOS

#MultipleMyeloma is a rare blood cancer that wreaks havoc on plasma cells in our bone marrow. Changes in myeloma cancer cells make the condition difficult to treat. We’re working to change that. Learn more about our clinical trial in multiple myeloma here: classic.clinicaltrials.gov/ct2/show/NCT05…

Tomorrow, our CEO Michel Detheux and CFO Matthew Gall will participate in a fireside chat at the H.C. Wainwright & Co. 25th Annual Global Investment Conference. Learn more about the event here hcwevents.com/annualconferen… $ITOS

September is Blood Cancer Awareness Month. #DYK some of the common signs and symptoms of #MultipleMyeloma include bone pain, nausea, constipation, loss of appetite, thirst, weight loss, among others. Learn more about symptoms and treatments mayoclinic.org/diseases-condi…

On this #WorldCancerResearchDay, we want to honor those who work tirelessly to continue to bring life-saving treatments to patients. Learn more about our work to develop targeted immunotherapies for people living with cancer. iteostherapeutics.com/pipeline/

We're excited to announce that we'll be participating at the Cantor Fitzgerald 2023 Global Healthcare Conference on September 27th. Join us to hear more about iTeos's programs to create highly differentiated immunotherapy treatments. cantor.com/our-company/co… $ITOS

Earlier this month, our CEO Michel Detheux and CFO Matthew Gall participated in a fireside chat at the H.C. Wainwright & Co. 25th Annual Global Investment Conference. Watch a recording here: investors.iteostherapeutics.com/events/event-d… $ITOS

Today we announced our third quarter 2023 financial results and provided a business update. Learn more here: investors.iteostherapeutics.com/news-releases/… $ITOS

We are pleased to welcome David K. Lee to our Board of Directors. Mr. Lee brings a wealth of experience in building biopharma businesses and driving company success at @servierpharma. We are confident that his expertise and leadership will be a ​valuable addition to iTeos.

Join us in San Francisco at the 2024 J.P. Morgan Healthcare Conference this Wednesday at 3pm PST. Learn about our exciting programs to create innovative immunotherapy treatments as we look forward to an exciting 2024! #ITOS #JPM24